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impaired immune response in hemodialysis patients to influenza
vaccination, even after a booster vaccine dose, and its real effect
on clinical outcomes and mortality is uncertain.2,3 Oseltamivir is
a neuramidase inhibitor licensed for the treatment of and prophy-
laxis for influenza. It is mainly renally eliminated and is cleared by
hemodialysis (molecular mass 312,4 g/mol). The optimal dose for
prophylaxis in hemodialysis patients in unknown. A population
pharmacokinetic study suggested 30 mg every other hemodialysis
session,4 whereas another clinical study on influenza A/H1N1 used
75mg every 5 days.5 These studies, however, have been performed in
the era of low-flux filters, while hemodiafiltration (HDF) and high-
flux dialyzers are the current standard of care.
In the 2017–2018 influenza season, we started oseltamivir 30
mg after each hemodialysis session in our dialysis unit because
of an emerging outbreak, even though all our patients had been
vaccinated with a standard-dose quadrivalent vaccine. More pre-
cisely, 5 new infections occurred in week 8 (Figure 1).
Additionally, the number of patients with influenza in our hospital,
a 1,182-bed acute- and tertiary-care hospital, was rising sharply
(Figure 1). In patients with influenza-like symptoms, testing for
influenza A and B on combined nasopharyngeal-throat swabs
was performed using real-time PCR on Taqman array cards. Of
the 137 patients in our dialysis unit, 130 (mean age, 73.1 ± 12 y;
36% female) provided informed consent to start the prophylactic
treatment. Prophylaxis was administered from week 10 up to week
14, given the dropping number of influenza cases in the hospital.
Of these 130 patients, 7 (5%) stopped prophylaxis early because of
their own decision (n= 3) or reported adverse effects: stomachache
(n= 1) andmuscle aches (n= 3). During the period of prophylaxis,
no case of influenza was detected in our dialysis unit (Figure 1). On
average, the number of patients screened for influenza was 2.58 per
week during the period of prophylaxis, and it had been 2.34 per
week during the 11 previous weeks, indicating continued screening
of patients with influenza-like symptoms. One week after the end
of prophylaxis, 1 case of influenza occurred in our unit.
Our observational study shows it is feasible and safe to admin-
ister prophylaxis for influenza with oseltamivir in hemodialysis
patients. To overcome potential enhanced elimination by high-flux
dialysis and HDF, we chose 30 mg after each hemodialysis session
in contrast to dosing every other hemodialysis session, as indicated
in the packet insert and as suggested by a population pharmacoki-
netic approach.4 Dosing after hemodialysis also allowed for opti-
mal compliance. No major adverse effects were observed, and
95% of the patients continued the prophylaxis during the predeter-
mined period. Although no control group was included, the
absence of new influenza cases in our hemodialysis, despite the
continuing intensive influenza epidemic in our hospital, indicates
the effectiveness of this strategy.
In light of recent findings that vaccination remains a subopti-
mal strategy to prevent influenza in hemodialysis patients,2,3 we
propose to administer oseltamivir prophylaxis during influenza
season as an additional protective measure. Further studies should
confirm the effectiveness of this strategy and explore its cost-
effectiveness.
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Fig. 1. The number of influenza cases per week is shown for the hospital (left axis) and
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To the Editor—Tuberculosis (TB) is one of the top 10 causes of
death worldwide.1 Despite efforts over the last two decades, control
of the infection at a global level is still out of reach; however,
decreasing trends in Mycobacterium tuberculosis incidence, out-
break, and mortality have been observed.2 The best estimate for
2017 is 1.3 million TB deaths (range, 1.2–1.4 million) with an addi-
tional 300,000 deaths (range, 266,000–335,000) resulting from TB
disease among HIV-positive people.3 Most cases are estimated to
have occurred in Asia and Africa, with the highest incidence in
China (1,410 million) and India (1,339 million) in 2017.3
According to the data,3,4 Iran has a low TB mortality rate (1 case
per 100,000 population, excluding cases of HIV plus TB), com-
pared to most neighboring countries such as Afghanistan
(29 per 100,000 population), Armenia (1.2 per 100,000 popula-
tion), Azerbaijan (8.7 per 100,000 population), Iraq (2.9 per
100,000 population), Turkmenistan (9.9 per 100,000 population),
and Pakistan (27 per 100,000 population). Moreover, according to
a report by the Ministry of Health and Medical Education of
Iran, from 1964 to 2016, the incidence of pulmonary TB with pos-
itive sputum smear in Iran decreased by >10 times to 5.7 per
100,000 population in 2016.5 But how has Iran succeeded in con-
trolling TB in a region with high burden of tuberculosis and multi-
drug-resistant (MDR) tuberculosis?
Because Iran is located in a special geographical location,
achieving this result requires huge financial cost, equipment,
and time investment for Iran. The country is surrounded by 2
countries with a high burdens of TB (ie, Pakistan and
Afghanistan) in the east as well as Iraq in the west (with which
Iran is involved in external and internal wars). In addition,
Azerbaijan to the north has a high prevalence of MDR-TB.
Thus, the challenge to control this disease is substantial, and its
success is admirable. There are several important reasons for
Iran’s success. (1) Continuation of free treatment and diagnosis
for TB patients plays a significant role in TB control. (2) Nine
regional TB laboratories in big cities including Tabriz, Shiraz,
Isfahan, Mashhad, Kermanshah, Zahedan, Gorgan, Ahvaz, and
Tehran distribute alerts about all TB incidents. (3) Improved phe-
notypic and genotypic diagnosis, treatment, and follow-up have
accompanied the increased quantity and quality of health care
in Iran over 50 years, despite economic sanctions. (4) The
addition of 3 multidrug-resistant TB treatment centers in Shiraz,
Mashhad, and Tabriz cities in southern, eastern and western
Iran, respectively, now cover all regions of Iran. (5) Cooperation
with the international community has improved, especially with
the World Health Organization. (6) The activities of university
centers in TB control have improved through skilled personnel
training and improving education for the poor regions and sub-
urbs. (7) Quality control programs for TB microbiology laborato-
ries have been implemented. (8) The number of private medical
diagnostic labs in the cities and the villages has grown substantially.
(9) Finally, the Ministry of Health and Medical Education on TB
program includes follow-up and continuous monitoring.
According to the policy objective of the Ministry of Health in
Iran, by the year 2025, the detection rate of pulmonary TBwill have
increased to >85% and the rate of treatment will have increased
to 90%.
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